• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What uniQure (QURE) Narrower Q3 Loss Means For Shareholders

    Simply Wall St·11/07/2026 11:25:25
    Listen to the news
    • uniQure reported third quarter 2026 revenue of US$5.2 million compared with US$3.7 million a year earlier, with the quarterly net loss narrowing to US$61.22 million from US$80.53 million and basic loss per share from continuing operations improving to US$0.88 from US$1.38.
    • Across the first nine months of 2026, uniQure recorded higher revenue of US$14.6 million versus US$10.53 million but a larger net loss of US$195.81 million compared with US$161.89 million, indicating heavier spending or cost pressures even as revenue increased.
    • The focus now turns to how uniQure's investment narrative incorporates higher quarterly revenue alongside a still substantial year-to-date loss profile.

    Scan how uniQure's high R&D spend and continued losses compare with other cash hungry developers by reviewing our curated list of 19 high quality undiscovered gems.

    What Is uniQure's Investment Narrative?

    To own uniQure, you have to be comfortable backing a research heavy gene therapy platform where commercial revenue is still small and the real story sits in the pipeline. The latest quarter fits that picture. Revenue of US$5.2 million remains modest next to a quarterly net loss of US$61.22 million, and the nine month loss of US$195.81 million points to capital intensive development. For a shareholder, the belief has to be that therapies like HEMGENIX and programs such as AMT 130 eventually justify years of high spend and continued losses.

    The recent earnings release does not radically change that thesis, but it does sharpen the near term focus on cash burn, execution in ongoing trials, and pricing power where uniQure already has a commercial product. In the short term, the key questions are whether management can keep funding the pipeline on acceptable terms and whether trial progress, regulatory updates, or commercial data can offset a share price that has fallen 53.3% over 90 days. With a volatile stock and a P/B of 5.1x compared with a US Biotechs industry average of 1.7x, patience and risk tolerance need to match the story.

    Even so, there is one structural pressure around capital and control that is easy to overlook until you reach ...

    There's only one way to know the right time to buy, sell or hold uniQure. Head to Simply Wall St's company report for the latest analysis of uniQure's Fair Value.

    NasdaqGS:QURE 1-Year Stock Price Chart
    NasdaqGS:QURE 1-Year Stock Price Chart

    Exploring Other Perspectives

    One significant swing factor for uniQure that bearish analysts keep highlighting is the risk that AMT 130 may take longer to translate into meaningful Huntington’s revenue. Before this report, the most pessimistic forecasts had 2029 revenue at around US$121.7 million and earnings still as low as a loss of US$329.8 million. That is very different from the more optimistic camp and shows how far apart expectations can be. Use this earnings release as an opportunity to compare those extremes and consider which version of the future you find more realistic.

    Explore 4 other uniQure fair value estimates, including one that suggests it could be worth just $27.96!

    Reach Your Own Conclusion

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so consider your own independent view.

    Looking For More Investment Ideas Beyond uniQure?

    If uniQure has sharpened your sense of risk, reward, and time horizon, you can use that momentum to widen your watchlist. The Simply Wall St Screener can help you quickly filter the market to match the kind of balance sheet strength, income profile, or upside potential you want to research next.

    • For investors who care most about financial resilience, you can start with companies that pair solid cash positions with conservative leverage by reviewing our list of solid balance sheet and fundamentals (24 results).
    • If you lean toward steadier income and want to focus on yield, you can scan through businesses offering robust payout profiles and consistent distributions via our 8 dividend fortresses.
    • When you are hunting for mispriced opportunities with quality fundamentals, you can focus on potential value ideas using the curated 39 high quality undervalued stocks.